Page 18 - பொது மன்னிப்பு சர்வதேச ஒன்றுபட்டது News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MedCity News ASCO 2021 recap: Lynparza’s lift, Grail goes on, LAG validation & more The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger counterparts and others forged their own paths with promising early results for new cancer drug targets. Shares0   The annual meeting of the America Society of Clinical Oncology came and went, and for the second year in a row, the pandemic meant that the cancer gathering was an all-digital affair. Big pharmaceutical companies grabbed most of the headlines with data supporting further development of some clinical candidates and in at least one case, potential expanded use of a blockbuster cancer drug as an earlier treatment. Targeted therapies have been gaining steam and this year’s conference saw the unveiling of data validating some new targets. Here’s a look back at some of the highlights

City ofUnited kingdomUnited statesNew south walesMerck keytrudaAndrew tuttKings college londonAmerica society of clinical oncologyInstitute of cancer researchConstellation pharmaceuticalsBristol myers squibbAmerica societyClinical oncologyNew england journalCancer researchMassachusetts based constellation